The Patent Finder

Develogen Aktiengesellschaft

Also on record
Records under this name other than patents Develogen Aktiengesellschaft holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Develogen Aktiengesellschaft

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,943,357Crystallographic Structure of MNK-1 and MNK-2 Proteins
Formerly held
Term ended
Term ended Oct 29, 2026 · Medium confidence
Term endedTerm ended Oct 29, 2026Medium confidence
US 8,697,713Pyrrolopyrimidines for Pharmaceutical Compositions
Formerly held
Lapsed on the fee record
Ended Apr 15, 2026 · High confidence
Lapsed on the fee recordEnded Apr 15, 2026High confidence
US 8,129,164Crystallographic Structure of MNK-1 and MNK-2 Proteins
Formerly held
Term ended
Term ended Mar 8, 2026 · Medium confidence
Term endedTerm ended Mar 8, 2026Medium confidence
US 9,029,323Neurturin conjugates for pharmaceutical use
Formerly held
Lapsed on the fee record
Ended May 12, 2023 · USPTO record
Lapsed on the fee recordEnded May 12, 2023USPTO record
US 8,071,607MNK1 or MNK2 Inhibitors
Formerly held
Lapsed on the fee record
Ended Dec 6, 2019 · High confidence
Lapsed on the fee recordEnded Dec 6, 2019High confidence
US 9,049,849Screening Methods for Compounds Useful for Treating Pancreatic Dysfunction
Formerly held
Lapsed on the fee record
Ended Jun 9, 2019 · High confidence
Lapsed on the fee recordEnded Jun 9, 2019High confidence
US 8,828,934Mnk KINASE HOMOLOGOUS PROTEINS INVOLVED IN THE REGULATION OF ENERGY HOMEOSTASIS AND ORGANELLE METABOLISM
Formerly held
Lapsed on the fee record
Ended Sep 9, 2018 · Medium confidence
Lapsed on the fee recordEnded Sep 9, 2018Medium confidence
US 8,772,233Method for promoting regeneration of pancreatic beta-cells by administering neurturin
Formerly held
Lapsed on the fee record
Ended Jul 8, 2018 · USPTO record
Lapsed on the fee recordEnded Jul 8, 2018USPTO record
US 8,633,201Thienopyrimidines Having MNK1/MNK2 Inhibiting Activity for Pharmaceutical Compositions
Formerly held
Lapsed on the fee record
Ended Jan 21, 2018 · High confidence
Lapsed on the fee recordEnded Jan 21, 2018High confidence
US 8,501,473Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
Formerly held
Lapsed on the fee record
Ended Aug 6, 2017 · USPTO record
Lapsed on the fee recordEnded Aug 6, 2017USPTO record
10 of 14 patents shown.
Pro members see all 14.
Pro members: see all 14 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited